We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vascular Biogenics Ltd | NASDAQ:VBLT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.156 | 0.1598 | 0.1599 | 0 | 01:00:00 |
☐
|
Rule 13d-1(b)
|
☒
|
Rule 13d-1(c)
|
☐
|
Rule 13d-1(d)
|
CUSIP No. M96883109
|
13G/A
|
Page 2 of 7 Pages
|
1. |
NAMES OF REPORTING PERSONS
Aurum Ventures M.K.I. Ltd.
|
||
2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ☐
(b) ☐
|
||
3. |
SEC USE ONLY
|
||
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
Israel
|
||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5. |
SOLE VOTING POWER
6,839,059 (1)
|
|
6. |
SHARED VOTING POWER
0
|
||
7. |
SOLE DISPOSITIVE POWER
6,839,059 (1)
|
||
8. |
SHARED DISPOSITIVE POWER
0
|
||
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,839,059 (1)
|
||
10. |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see
instructions)
☐
|
||
11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
13.9% (2)
|
||
12. |
TYPE OF REPORTING PERSON (see instructions)
CO
|
(1) |
Includes 1,269,841 Ordinary Shares that underlie warrants to purchase Ordinary Shares that are held by the Reporting Person and that are currently exercisable.
|
(2) |
Percentage is based on 47,896,736 Ordinary Shares of the Issuer that were issued and outstanding as of May 27, 2020, as set forth in the Issuer’s registration statement on Form F-1, filed with the Securities and Exchange Commission (the “SEC”) on June 1, 2020, as adjusted upwards to include an additional 1,269,841 Ordinary Shares that underlie warrants held by the Reporting Person that are currently exercisable.
|
CUSIP No. M96883109
|
13G/A
|
Page 3 of 7 Pages
|
1. |
NAMES OF REPORTING PERSONS
Morris Kahn
|
||
2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ☐
(b) ☐
|
||
3. |
SEC USE ONLY
|
||
4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
Israel
|
||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
5. |
SOLE VOTING POWER
0
|
|
6. |
SHARED VOTING POWER
6,839,059 (1)
|
||
7. |
SOLE DISPOSITIVE POWER
0
|
||
8. |
SHARED DISPOSITIVE POWER
6,839,059 (1)
|
||
9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,839,059 (1)
|
||
10. |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see
instructions)
☐
|
||
11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
13.9% (2)
|
||
12. |
TYPE OF REPORTING PERSON (see instructions)
IN
|
(1)
|
Includes 1,269,841 Ordinary Shares that underlie warrants to purchase Ordinary Shares that are held by Aurum Ventures M.K.I.
Ltd. (with respect to which the Reporting Person shares voting and dispositive power) and that are currently exercisable.
|
(2)
|
Percentage is based on 47,896,736 Ordinary Shares of the Issuer that were issued and outstanding as of May 27, 2020, as set forth in the Issuer’s registration statement on Form F-1, filed with the SEC on June 1, 2020, as adjusted upwards to include an additional 1,269,841 Ordinary Shares that underlie warrants held by Aurum Ventures M.K.I. Ltd. (with respect to which the Reporting Person shares voting and dispositive power)
and that are currently exercisable.
|
(a)
|
Name of Issuer
Vascular Biogenics Ltd.
|
(b)
|
Address of Issuer’s Principal Executive Offices
8 HaSatat St. Modi’in, Israel 7178106
|
(a)
|
Name of Person Filing:
This Amendment No. 2 (this “Amendment No. 2”) to the Statement of Beneficial Ownership on Schedule 13G that was
filed on February 17, 2015 (the “Statement”), as amended by Amendment No. 1 thereto, filed on February 13, 2020 (“Amendment No. 1”), is being filed by each of:
(i) Aurum Ventures M.K.I. Ltd. (the “Reporting Entity”)
(ii) Morris Kahn (the “Reporting Individual”)
The Reporting Individual is the sole beneficial shareholder of the Reporting Entity. The Reporting Entity and the Reporting Individual are referred
to herein collectively as the “Reporting Persons”.
This Amendment No. 2 reports the acquisition, by the Reporting Persons, since the filing of Amendment No. 1, of beneficial
ownership over an additional 1,269,841 Ordinary Shares and an additional 1,269,841 Ordinary Shares underlying warrants to purchase Ordinary Shares (all of which warrants are currently exercisable), which were acquired by the Reporting
Entity in a public offering that was consummated by the Issuer on May 12, 2020.
|
(b)
|
Address of Principal Business Office or, if None, Residence:
The principal business office of each of the Reporting Persons is c/o Aurum Group, 16 Abba Hillel Road
Ramat Gan 5250608, Israel
|
(c)
|
Citizenship:
The Reporting Entity is organized in Israel. The Reporting Individual is a citizen of the State of Israel.
|
(d)
|
Title of Class of Securities
Ordinary Shares, New Israeli Shekel (“NIS”) 0.01 par value
per share (“Ordinary Shares”)
|
(e)
|
CUSIP Number
M96883109
|
(a)
|
☐ |
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
|
(b)
|
☐ |
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
|
(c)
|
☐ |
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
|
(d)
|
☐ |
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
|
(e)
|
☐ |
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
|
(f)
|
☐ |
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
|
(g)
|
☐ |
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
|
(h)
|
☐ |
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
(i)
|
☐ |
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment
Company Act of 1940 (15 U.S.C. 80a-3);
|
(j)
|
☐ |
Group, in accordance with §240.13d-1(b)(1)(ii)(J).
|
(a)
|
Amount beneficially owned: 6,839,059 Ordinary Shares (consisting of 5,569,218 Ordinary Shares and 1,269,841
additional Ordinary Shares underlying warrants to purchase Ordinary Shares that are currently exercisable)
|
(b)
|
Percent of class: 13.9%*
*Such percentage is based on 47,896,736 Ordinary Shares of the Issuer that were issued and outstanding as of May 27, 2020, as set forth in the Issuer’s registration statement
on Form F-1, filed with the Securities and Exchange Commission on June 1, 2020, as adjusted upwards to include an additional 1,269,841 Ordinary Shares that underlie currently-exercisable warrants held by the Reporting Entity (with respect to which the Reporting
Person shares voting and dispositive power).
|
|||
(c)
|
Number of shares as to which the person has:
|
|||
(i)
|
Sole power to vote or to direct
the vote: Reporting Entity: 6,839,059
Reporting Individual: 0
|
|||
(ii)
|
Shared power to vote or to direct
the vote: Reporting Entity: 0
Reporting Individual: 6,839,059
|
|||
(iii)
|
Sole power to dispose or to
direct the disposition of: Reporting Entity: 6,839,059
Reporting Individual: 0
|
|||
(iv)
|
Shared power to dispose or to
direct the disposition of: Reporting Entity: 0
Reporting Individual: 6,839,059
|
AURUM VENTURES M.K.I. LTD.
By: /s/ Nir Dror-Darwish
Name:Nir Dror-Darwish
Title: Authorized Signatory
By: /s/ Ilan Lior
Name: Ilan Lior
Title: Authorized Signatory
Date: August 3, 2020
/s/ Morris Kahn
MORRIS KAHN
Date: August 3, 2020
|
1 Year Vascular Biogenics Chart |
1 Month Vascular Biogenics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions